Acquiring Bellus Health gives GSK a drug for recurrent chronic cough that could offer a better side effect profile compared to a Merck drug that addresses the same target. Bayer was also pursuing the target, but stopped work on its drug candidate last year.
Roche’s deep oncology pipeline is adding a drug candidate from Repare Therapeutics that works by interfering with a DNA repair mechanism of cancer cells. Repare receives $125 million up front and it retains the right to share in the development and commercialization of the drug, camonsertib.
A new independent study from Phyx Primary Care’s Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices.
The Canadian Space Agency has inked a deal with med tech company Hexoskin to develop wearables with an eye to supporting remote monitoring of their astronauts' vital signs in space.
Invented by two outdoors enthusiasts-turned-dads, Hoko, which comes with an activities book, is supposed to make sure children are comfortable so parents can plan family adventures without being interrupted by crying or tantrums. Our warped minds had other thoughts.